ErpeCream® — A first-in-class topical immunomodulator for recurrent genital HSV-2
Patent-protected nanoemulsion. No systemic exposure. Zero adverse events in Phase II. Available now as registered dermocosmetic. Phase IIb head-to-head vs acyclovir in progress.
How ErpeCream® works — beyond antivirals
Viral Entry Block
Nanoemulsion particles create a physical barrier that prevents HSV virions from attaching to epithelial cells.
Direct Antiviral Action
Botanical actives interfere with HSV replication cycle, reducing viral load at the site of infection.
Local Immunomodulation
Reduction of TNF-α, IL-6, and oxidative stress markers. Supports local immune response without systemic exposure.
Tissue Repair
Accelerates epithelial barrier restoration and tissue healing, contributing to faster lesion resolution.
Formulation Characteristics
O/W Nanoemulsion
Compatible with vaginal mucosa • Iso-osmotic • High stability
6 Synergistic Botanical Actives
Click each ingredient to discover the mechanism of action
Fenugreek
Trigonella Foenum-graecum
SoothingFenugreek
MechanismSoothing and protective action on mucosa. Reduces irritation and promotes comfort during application.
Oak Gall
Quercus Infectoria
Astringent, AntimicrobialOak Gall
MechanismAstringent and antimicrobial properties. Contributes to local microbial proliferation control.
Pueraria
Pueraria Mirifica
AntiviralPueraria
MechanismDocumented antiviral activity. Supports the body's natural response against viral infections.
Witch Hazel
Hamamelis Virginiana
Soothing, AstringentWitch Hazel
MechanismCombination of soothing and astringent properties. Calms irritation and promotes tissue healing.
Ginseng
Panax Ginseng
ImmunostimulantGinseng
MechanismImmunostimulant action. Enhances local immune defenses for a more effective response.
Echinacea
Echinacea Angustifolia
Immune SupportEchinacea
MechanismRecognized immune support. Stimulates macrophage activity and protective cytokine production.
Functional Excipients
Differentiation vs Standard of Care
| Product | Route | Clinical Response | Limitations |
|---|---|---|---|
| Sitavig® | Buccal | 18–20% | Slow onset, systemic exposure |
| Valtrex® | Oral | 30–35% | Systemic side effects, Rx only, growing resistance |
| Zovirax® Topical | Topical | ~20% | 5x/day application, low adherence |
| ErpeCream® | Topical | 97% in 96h* | No systemic absorption. Zero adverse events |
* Phase II open-label exploratory study, n=42. Non-head-to-head comparison. Response rates for comparators based on published literature.
Formulation Highlights
Two Clear Positionings
Registered dermocosmetic product
CPNP (EU) + UK.GOV registered. Available in pharmacies, dermatology channels, and online.
Distribution active: Europe, Gulf, Latam. New partners sought.
Phase IIb/III Clinical Development
- Phase IIb: 80 patients, head-to-head vs acyclovir. CRO: PPD (Thermo Fisher). Ref. BC147404-01.
- Phase III: 420 patients, 7 EU countries, 25 sites, ~29 months. EMA/FDA-aligned.
- Target: Rx prescription drug. Licensing / M&A trigger post-Phase IIb readout.
Request Free Samples
Interested in distributing ErpeCream in your territory?
We offer up to 5 free samples for companies and professionals interested in distribution. You only pay shipping costs.
All efficacy and safety data for ErpeCream® are from an exploratory Phase II study (n=42), non-comparative. Subject to confirmation in planned Phase IIb RCT. ErpeCream® is investigational as a pharmaceutical and not approved by any regulatory authority. Cosmetic registration does not imply therapeutic claims.